Studying obesity-associated changes in white blood cell count (WBCs) and in some WBC-derived inflammatory markers in type 2 diabetic Patients under treatment with metformin monotherapy

Authors

  • zeinab sarem Tishreen University

Abstract

This study aimed to evaluate the changes in (WBCs) and some WBC-derived inflammatory markers in type 2 diabetic patients under treatment with metformin monotherapy. A total of 47 metformin-treated T2DM patients were enrolled in this study from Tishreen University Hospital, Lattakia, Syria for a period of 3 months and divided into three BMI-based groups.  FBG level, WBCs count, percentages of neutrophils and lymphocytes were measured at two time points during the treatment with metformin. The neutrophil/lymphocyte ratio (NLR), the platelet/ lymphocyte ratio (PLR) and the systemic immune-inflammation index (SII) were calculated and compared. Because the mean duration of T2DM diagnosis and using metformin as monotherapy by the studied patients were 8 ± 4 months, the mean value of all measured variables were within the normal reference ranges. No statistically significant change in total WBCs (7.278±0.99vs7.237±1.04 103/mm3), neutrophil percent (58.03±5.85 vs58.619±5. 53%), lymphocyte percent (34.174±5.90 vs33.685±5.44%) and platelets counts (237.667±26.17 vs 239.482± 21.76 103/mm3), NLR (1.789±0.56vs1.796±0.46), PLR (99.327±21.19 vs 103.685±28.65) and SII (417.726±116.89 vs 430.058±114.7) were observed between the begin of the study and after 3 months. Although there was a significant decrease in WBCs count (6.32±0.66*103/mm3) (P =0.004) and a significant increase in PLR (118.73±33.48) (P =0.046) in the obese group compared with WBCs count (8.5±0.79*103/mm3) and PLR (83.04±5.8) in the normal weight group at the begin of the study, these differences were not significant after 3 months of continuous using of metformin. Metformin may prevent or delay the development and progression of cardiovascular diseases among patients with type 2 diabetes, by exerting anti-inflammatory effect and controlling the changes in some inflammatory indices like WBC- derived inflammatory markers, regardless of presence or absence of obesity.

 

Downloads

Published

2024-08-22

How to Cite

1.
صارم ز. Studying obesity-associated changes in white blood cell count (WBCs) and in some WBC-derived inflammatory markers in type 2 diabetic Patients under treatment with metformin monotherapy. Tuj-hlth [Internet]. 2024Aug.22 [cited 2024Sep.1];46(3):87-100. Available from: https://journal.tishreen.edu.sy/index.php/hlthscnc/article/view/17346

Issue

Vol. 46 No. 3 (2024): Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

 Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series   .  The Readers have the right to send, print and subscribe to the initial version of the article, and the title of  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series  Publisher

journal uses a CC BY-NC-SA license which mean

You are free to:

  • Adapt — remix, transform, and build upon the material
  •  
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

 

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.